Dendreon shares soar on Provenge survival data

Shares of Dendreon shot up this morning after it released new data showing that patients taking the cosely watched prostate cancer therapy Provenge were less likely to die than patients taking a placebo. But Forbes' Matthew Herper notes that the data may not prove that the drug is effective--even if it does save lives. Release | Report